NASDAQ:PBLS Parabilis Medicines (PBLS) Stock Price, News & Analysis $37.07 +1.40 (+3.92%) As of 08/14/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Parabilis Medicines Stock (NASDAQ:PBLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Parabilis Medicines alerts:Sign Up Key Stats Today's Range$34.78▼$37.9950-Day Range$25.01▼$37.4152-Week Range$24.51▼$37.99Volume290,894 shsAverage Volume370,349 shsMarket Capitalization$4.38 billionP/E RatioN/ADividend YieldN/APrice Target$41.67Consensus RatingBuy Company Overview Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass. Read More Parabilis Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScorePBLS MarketRank™: Parabilis Medicines scored higher than 45% of companies evaluated by MarketBeat, and ranked 662nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingParabilis Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialParabilis Medicines has a consensus price target of $41.67, representing about 12.4% upside from its current price of $37.07.Amount of Analyst CoverageParabilis Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Parabilis Medicines' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Parabilis Medicines are expected to decrease in the coming year, from ($1.40) to ($1.63) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.33% of the float of Parabilis Medicines has been sold short.Short Interest Ratio / Days to CoverParabilis Medicines has a short interest ratio ("days to cover") of 12.82, which indicates bearish sentiment.Change versus previous monthShort interest in Parabilis Medicines has recently increased by 29.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldParabilis Medicines does not currently pay a dividend.Dividend GrowthParabilis Medicines does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.09 News SentimentParabilis Medicines has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Parabilis Medicines this week, compared to 3 articles on an average week. Company Ownership3.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Parabilis Medicines in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $10,723,528.00 in company stock, which represents 0.2448% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Parabilis Medicines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,723,528.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsParabilis Medicines has minimal institutional ownership at this time.Read more about Parabilis Medicines' insider trading history. Receive PBLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Parabilis Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBLS Stock News HeadlinesParabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable PlatformAugust 14 at 11:00 AM | seekingalpha.comParabilis Medicines Q2 Loss Narrows; Shares Rise Pre-BellAugust 13 at 7:32 PM | finance.yahoo.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Parabilis Medicines: Q2 Earnings SnapshotAugust 13 at 9:30 AM | finance.yahoo.comParabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13 at 7:00 AM | globenewswire.comThis Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayJuly 6, 2026 | benzinga.comPBLS Parabilis Medicines, Inc.July 2, 2026 | seekingalpha.comThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already InvestedJune 27, 2026 | fool.comSee More Headlines PBLS Stock Analysis - Frequently Asked Questions How have PBLS shares performed this year? Parabilis Medicines' stock was trading at $31.60 on June 10, 2026. Since then, PBLS shares have increased by 17.3% and is now trading at $37.07. How were Parabilis Medicines' earnings last quarter? Parabilis Medicines, Inc. (NASDAQ:PBLS) announced its earnings results on Thursday, August, 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $2.16. The firm earned $0.15 million during the quarter. When did Parabilis Medicines IPO? Parabilis Medicines (PBLS) raised $603 million in an IPO on Wednesday, June 10th 2026. The company issued 33,500,000 shares at a price of $17.00-$19.00 per share. When did Parabilis Medicines' quiet period expire? Parabilis Medicines's quiet period expired on Monday, July 20th. Parabilis Medicines had issued 33,500,000 shares in its initial public offering on June 10th. The total size of the offering was $670,000,000 based on an initial share price of $20.00. During Parabilis Medicines' quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Parabilis Medicines' major shareholders? Parabilis Medicines' top institutional investors include ARCH Venture Management LLC (5.43%), Alphabet Inc. (4.16%), Jupiter Topco LLC (1.94%) and ICONIQ Capital LLC (0.30%). View institutional ownership trends. How do I buy shares of Parabilis Medicines? Shares of PBLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today8/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PBLS CIK1657677 Webparabilismed.com Phone617-945-9510FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Parabilis Medicines$41.67 High Price Target$45.00 Low Price Target$40.00 Potential Upside/Downside+12.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares118,150,000Free FloatN/AMarket Cap$4.38 billion OptionableN/A BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PBLS) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe Greatest Wealth Transfer Since the Internet Boom Just StartedWall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...Altimetry | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Parabilis Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Parabilis Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
